Reozalimab  (Synonyms: LY3434172; IBI-318)

Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC₅₀ of 2.27 nM and an EC₅₀ of 0.080 nM against human PD-1, as well as an IC₅₀ of 0.75 nM and an EC₅₀ of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer^[1][2].

Ig(G1-kappa_G1-lambda2)

Human IgG1 kappa, Isotype Control

Human

PDCD1 & CD274

Reozalimab (1 h) blocks the interactions of PD-1/PD-L2 and PD-L1/CD80, with corresponding IC₅₀ values of 2.27 nM and 0.75 nM, respectively, and also inhibits the binding of PD-1/PD-L1^[2].
Reozalimab binds to human and cynomolgus monkey PD-1 and PD-L1 with high affinity, but does not bind to mouse or rat PD-1 or PD-L1^[2].
Reozalimab (1 h) specifically binds to CHO-K1 cells expressing PD-1 and PD-L1, with corresponding EC₅₀ values of 2.39 nM and 0.589 nM^[2].
Reozalimab (6 h) enhances T cell activation in the co-culture system of CHO-K1 cells expressing PD-L1 or co-expressing PD-L1⁺PD-L2 with NFAT-luc2/PD1 Jurkat cells, with EC₅₀ values of 0.12 nM and 0.18 nM, respectively^[2].
Reozalimab (66 h) enhances the activation of naive human CD4 T cells in allogeneic MLR, with an EC₅₀ of 0.01 nM^[2].
Reozalimab enhances primary human pan-T cell-mediated killing of HEL 92.1.7 tumor cells, with an EC₅₀ of 0.005 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reozalimab (0.02-2 mg/kg; intraperitoneal injection; once weekly) induces potent dose-dependent anti-tumor activity in a humanized HCC827 non-small cell lung cancer mouse model^[2].
Reozalimab (0.0025-0.25 mg/kg; i.p.; once weekly) exhibits significant anti-tumor activity in the prophylactic NCI-H292 NSCLC humanized mouse model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI] & 29126  [NCBI]

Q15116 & Q9NZQ7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.55 kDa

2445259-99-2

Liquid

Colorless to light yellow

[Reozalimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Ig(G1-kappa_G1-lambda2)

• [1]. Vijaya Raghavan PATTABIRAMAN, et al. Synthetic il-7 and il-7 immunocytokines. WO2023281484A1. 2024-01-09

  [2]. Kotanides H, et al. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunol Res. 2020 Oct;8(10):1300-1310.  [Content Brief]